tbuckley/cabot-search huggingface dataset:
Abstract 18834: IF1 And ApoA-I Serum Concentrations, but Not HDL-cholesterol, Predict Mortality in Coronary Artery Disease Patients: The Genes Study
Authors: Annelise Genoux, Jean-Bernard Ruidavets, Jean Ferrières, Vanina Bongard, Paul-Louis Vervueren, Guillaume Combes, Dorota Taraszkiewicz, Meyer Elbaz, Bertrand Perret, Laurent O Martinez
Journal: Circulation (2015)

Introduction: High-density lipoprotein cholesterol (HDL-C) may not be the best clinical measure of HDL for assessing cardiovascular risk. Serum inhibitor factor 1 (IF1), an endogenous inhibitor of the ecto-F1-ATPase apoA-I receptor, has been identified as an independent determinant of HDL-C associated with low risk of coronary artery disease (CAD). Objective: To determine the relationship between serum IF1 concentration and mortality in stable CAD patients in comparison with HDL-C and apoA-I Methods: Serum IF1 was measured in 577 coronary male patients (enrollment age 45-74 years; enrollment period, 2001-2004) from the GENES (Genetique et ENvironement en Europe du Sud) study. Vital status was assessed yearly through December 31, 2013. Results: During a median follow up of 11 years, mortality rate was 29.5%. Cardiovascular mortality accounted for the majority (62.5%) of deaths. Serum IF1 (median value: 0.42 mg/mL) was positively correlated with HDL-C and apoA-I, and negatively with triglycerides and the severity of CAD (Gensini, Duke-Jeopardy scores). Mortality was lower the higher the quartile score for IF1 and apoA-I, but not for HDL-C. Inverse associations of IF1 and apoA-I with mortality remained significant, even after multivariate adjustments for classical cardiovascular risk factors - age, smoking, diabetes, dyslipidemia, waist circumference, physical activity and CRP. Furthermore, associations of the highest IF1 quartile with mortality reduction remained significant after further adjustment for clinical parameters proven to be predictive of complications in CAD patients, such as ankle-brachial index, heart rate and CAD duration. Interestingly, when levels of both IF1 and apoA-I were high, mortality was much lower than when only one of these was high. Conclusions: IF1 is a new biological marker strongly predictive of mortality in CAD patients. Among patients with normal or elevated apoA-I levels, IF1 measurement may help to identify those who are at low risk of complications and those who are not. IF1 measurement could be use in a panel of other emerging biomarkers that have been proven to be better than HDL-C level, for the better assessment of cardiovascular risk or in the setting of pharmacotherapy.
Circulating Glioma Cells Exhibit Stem Cell-like Properties
Authors: Tianrun Liu, Haineng Xu, Menggui Huang, Wenjuan Ma, Deeksha Saxena, Robert A. Lustig, Michelle Alonso-Basanta, Zhenfeng Zhang, Donald M. O'Rourke, Lin Zhang, Yanqing Gong, Gary D. Kao, Jay F. Dorsey, Yi Fan
Journal: Cancer Research (2018)

: Circulating tumor cells (CTC) are known to be present in the blood of patients with glioblastoma (GBM). Here we report that GBM-derived CTC possess a cancer stem cell (CSC)-like phenotype and contribute to local tumorigenesis and recurrence by the process of self-seeding. Genetic probes showed that mouse GBM-derived CTC exhibited Sox2/ETn transcriptional activation and expressed glioma CSC markers, consistent with robust expression of stemness-associated genes including SOX2, OCT4, and NANOG in human GBM patient-derived samples containing CTC. A transgenic mouse model demonstrated that CTC returned to the primary tumor and generated new tumors with enhanced tumorigenic capacity. These CTCs were resistant to radiotherapy and chemotherapy and to circulation stress-induced cell apoptosis. Single-cell RNA-seq analysis revealed that Wnt activation induced stemness and chemoresistance in CTC. Collectively, these findings identify GBM-derived CTC as CSC-like cells and suggest that targeting Wnt may offer therapeutic opportunities for eliminating these treatment-refractory cells in GBM. SIGNIFICANCE: These findings identify CTCs as an alternative source for in situ tumor invasion and recurrence through local micrometastasis, warranting eradication of systemic "out-of-tumor" CTCs as a promising new therapeutic opportunity for GBM.
P3.12-14 Genomic Profiling of Chinese Small Cell Lung Cancer and the Implications for Therapy
Authors: H. Zhong, Y. Wang, J. Hu, J. Guo, Y. Shang, M. Zheng, J. Zhao, Y. Li, J. Xie, H. Guo, J. Hu, A. Wang, W. Wang, W. Shi, K. Wang, M. Yao
Journal: Journal of Thoracic Oncology (2018)
BP: serum anti-BP180 IgG levels, mortality and Karnofsky score
Authors: M.M. Holtsche, S. Goletz, N. van Beek, D. Zillikens, S. Benoit, K. Harman, S. Walton, J. English, M. Sticherling, A. Chapman, N.J. Levell, R. Groves, H.C. Williams, I.R. König, E. Schmidt
Journal: British Journal of Dermatology (2018)

Bullous pemphigoid (BP) is a rare, chronic skin disease that causes blistering and severe itching, mainly in elderly patients. It is an autoimmune skin disease, in which the body's own immune system is directed against structures of the skin. Specific proteins, named autoantibodies, are produced and lead to inflammation. It affects about 259 per million people in Germany. In a recent published clinical trial, two different therapies for BP were compared in 253 BP patients in the U.K. and Germany. This additional study, again from Germany and the U.K., aimed to find out if there are any markers in the blood of these patients that tell us about the course of the disease. Therefore the authors investigated the blood of 143 patients taking part in a trial called the BLISTER trial. Several tests were performed to check for the amount of autoantibodies in the blood of these patients. Afterwards the results were linked with basic parameters including age, general condition, number of blisters, side effects, and mortality. The study revealed that patients with a poor general condition had higher levels of both specific autoantibodies which cause the disease. Patients who died within one year of inclusion to the study had higher amounts of one of the specific autoantibodies. The presence of the other specific autoantibody was more frequent in older patients. In conclusion, analyzing the autoantibody profile not only helps in diagnosis, but may also be helpful in predicting the course of the disease.
P3.CR-15 Squamous Cell Carcinoma Diagnosed While on Immunotherapy for Lung Adenocarcinoma: A Unique Clinical Case
Authors: S. Coelho, F. Carneiro, A. Rodrigues, J. Cárdia, C. Ferreira, A. Cunha, A. Teixeira, M. Soares
Journal: Journal of Thoracic Oncology (2018)
Abstract 18419: A Novel Class of Anti-inflammatory Binding Proteins Targeting αMβ2: in vivo Inhibition of Activated Monocytes in Intravital Microscopy
Authors: Xavier Tonnar, Patrick Siegel, Christoph Olivier, Thomas Helbing, Karlheinz Peter, Martin Moser, Christoph Bode, Philipp Diehl
Journal: Circulation (2017)

Introduction: Activated leukocytes mediate vascular inflammation. The leukocyte integrin αMβ2 (Mac-1) with its activation specific epitope (I-domain) is strongly involved in leukocyte adhesion to e...
Antimicrobial resistance surveillance in Europe and beyond
Authors: Gunnar Skov Simonsen
Journal: Eurosurveillance (2018)

Preview this article: Antimicrobial resistance surveillance in Europe and beyond, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/23/42/eurosurv-23-42-1-1.gif
When Will the Surgical Community Acknowledge the Evidence Regarding Prophylaxis With Oral Antibiotics for Scheduled Colorectal Operations?
Authors: E. Patchen Dellinger
Journal: JAMA Network Open (2018)

James W. T. Toh, MBBS, BSc, FRACS; Kevin Phan, MBBS; Kerry Hitos, BSc, PhD; Nimalan Pathma-Nathan, MBBS, MMed, FRACS; Toufic El-Khoury, MBBS, MS, FRACS; Arthur J. Richardson, MBBS, DCS, FRACS; Gary Morgan, MBBS, BDS, FRACS; Alexander Engel, MD, PhD, EBSQ; Grahame Ctercteko, MD, FRACS
Should Aspirin Be Routinely Used for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty?
Authors: Robert S. Sterling, Elliott R. Haut
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Stress Computed Tomography Perfusion Versus Fractional Flow Reserve CT Derived in Suspected Coronary Artery Disease
Authors: Gianluca Pontone, Andrea Baggiano, Daniele Andreini, Andrea I. Guaricci, Marco Guglielmo, Giuseppe Muscogiuri, Laura Fusini, Fabio Fazzari, Saima Mushtaq, Edoardo Conte, Giuseppe Calligaris, Stefano De Martini, Cristina Ferrari, Stefano Galli, Luca Grancini, Paolo Ravagnani, Giovanni Teruzzi, Daniela Trabattoni, Franco Fabbiocchi, Alessandro Lualdi, Piero Montorsi, Mark G. Rabbat, Antonio L. Bartorelli, Mauro Pepi
Journal: JACC. Cardiovascular imaging (2018)
Protection of coronary reperfusion injury by a calcium antagonist.
Authors: Masahiko Kinoshita, Yoshio Okada, Mizuo Miyazaki, Hideki Okunishi, Noboru Toda, Yukio Takayama, Shotaro Kato, Iwao Mashiro, Kenichi Mitsunami, Masakazu Motomura, Seiichi Kawakita, Atsumi Mori, Jun Sono
Journal: Circulation (1980)
Abstract A15: SMC2 role in regulating tumor angiogenesis via FGF signaling
Authors: Ghada M. Sharif, Marcel O. Schmidt, Casey Shuptrine, Weiner M. Louis, Anna T. Riegel, Anton Wellstein
Journal: Cancer Research (2016)

Abstract Fibroblast growth factors (FGFs) play a crucial role during embryonic development, tissue homeostasis, wound healing and angiogenesis. FGF-binding protein 1 (FGFBP1) is a secreted protein that binds FGFs stored in the extracellular matrix and transports them to their receptor, therefore they can modulate FGF signaling. FGFBP1 contributes to the progression of many cancers including colon, pancreas and squamous cell cancer. It acts as an angiogenic switch during tumor development. E0771 cells, a murine mammary carcinoma cell line, was subcutaneously injected into syngeneic C57BL/6 mice. While these cells form aggressive tumors within two weeks and metastasize to the lungs in wild type FGFBP1 (FGFBP1+/+) mice, there was no tumor growth or metastasis in FGFBP1 knock out (FGFBP1-/-) mice. A genome-wide shRNA library screen revealed a novel role for structural maintenance of the chromosome 2 (SMC2) in compensating for the loss of FGFBP1 in the stroma of FGFBP1-/- mice. E0771 cells with SMC2 knock down (KD) or CRISPR targeting SMC2 formed aggressive tumors in FGFBP1-/- mice and metastasized to the lungs. Surprisingly, FGFBP1 expression level was 32 folds lower in SMC2 KD E0771 cells yet FGF2 was 16 folds up in the tumors from SMC2 KD E0771 cells. Tumor histology shows impaired and leaky angiogenesis in FGFBP1-/- compared to FGFBP1+/+ mice. Furthermore, higher levels of GM-CSF and G-CSF were detected in the conditioned media (CM) of SMC2 KD E0771 cells compared to control cells suggesting differential immune cell recruitment. Also, an endothelial monolayer exposed to CM from SMC2 KD E0771 cells showed delayed wound closure and loose junctions suggesting a tendency for endothelium disintegration and initiation of blood vessel formation. Interestingly, the CM effect was blocked using PD173074, a pan FGFR inhibitor. In conclusion, SMC2 demonstrate a role in regulating FGF signaling which affects the course of angiogenesis during tumor development. Note: This abstract was not presented at the conference. Citation Format: Ghada M. Sharif, Marcel O. Schmidt, Casey Shuptrine, Weiner M. Louis, Anna T. Riegel, Anton Wellstein. SMC2 role in regulating tumor angiogenesis via FGF signaling. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr A15.
PPARγ is a major regulator of branched-chain amino acid blood levels and catabolism in white and brown adipose tissues
Authors: Pierre-Gilles Blanchard, Rafael J. Moreira, Érique Castro, Alexandre Caron, Marie Côté, Maynara L. Andrade, Tiago E. Oliveira, Milene Ortiz-Silva, Albert S. Peixoto, France Anne Dias, Yves Gélinas, Renata Guerra-Sá, Yves Deshaies, William T. Festuccia
Journal: Metabolism (2018)
PTU-063 Faecal calprotectin – time to re-draw the line
Authors: RN Patel, P Gyawali, V Clough, Z Khatami
Journal: Gut (2017)

Introduction  Faecal calprotectin (FCP) is a useful investigation for supporting a diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) (1). The cut off for a positive result remains controversial and has a significant impact on prompting invasive procedures and use of health care resources (2). We reviewed the impact of a local IBS/IBD pathway on patient outcomes and sought an evidence based threshold for a positive FCP result.  Method  We reviewed the FCP requests sent by primary care physicians in Barking, Havering and Redbridge University Trust (BHRUT) from November 2015 to March 2016. BHRUT uses a quantitative fluorescence enzyme immunoassay (FEIA); EliA Calprotectin 2. Initial thresholds for negative and indeterminate FCP results were set at   Results  1157 FCP requests were made between 09/11/15 and 31/03/16 with a female preponderance (60.9%). 26% of requests were inappropriate for age ( 60 years). Of 50 patients in the indeterminate group (30–75 ug/g), 9 were referred to gastroenterology (18%). 7 (77.8%) patients had a colonoscopy and none were diagnosed with IBD. Between July 2015 and August 2016; 93 FCP results that were negative or indeterminate were paired with their repeat samples. 78 (83.9%) remained   Reasons for FCP request (Table 1)  Conclusion  The FCP threshold of 50 ug/g suggested by NICE is obtained from pooled data using a variety of methods and should not be applied universally across hospital trusts. No patients at BHRUT with an FCP in the indeterminate range had evidence of IBD at colonoscopy. We suggest increasing the positive cut-off level for referral to gastroenterology to >75 ug/g. Repeating an indeterminate result did not change the initial diagnosis. Greater awareness of age appropriate FCP requests is required in primary care with older patients allocated to an alternative pathway.  References  . Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. Diagnostics guidance [DG11]. National Institute for Health and Care Excellence. Published date: October 2013.  . Faecal Calprotectin testing in Primary Care. NHS Technology Adoption Centre. Published date: April 2013.  Disclosure of Interest  None Declared
Precision Psychiatry—Yes, but Precisely What?
Authors: Ana Gómez-Carrillo, Timothé Langlois-Thérien, Laurence J. Kirmayer
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial
Authors: Petra Hissink Muller, Danielle M C Brinkman, Dieneke Schonenberg-Meinema, Wytse Bastiaan van den Bosch, Yvonne Koopman-Keemink, Isabel C J Brederije, Peter W Bekkering, Taco W Kuijpers, Marion Van Rossum, Lisette WA van Suijlekom-Smit, J Merlijn van den Berg, Stefan Boehringer, Cornelia F Allaart, R ten Cate
Journal: Annals of the Rheumatic Diseases (2018)

Question Which is the best strategy to achieve (drug-free) inactive disease in juvenile idiopathic arthritis (JIA)? Methods In a randomised, single-blinded, study in disease-modifying anti-rheumatic drug (DMARD)-naive patients with JIA, three treatment-strategies were compared: (1) sequential DMARD-monotherapy (sulfasalazine or methotrexate (MTX)), (2) combination therapy MTX + 6 weeks prednisolone and (3) combination therapy MTX +etanercept. Treatment-to-target entailed 3-monthly DMARD/biological adjustments in case of persistent disease activity, with drug tapering to nil in case of inactive disease. After 24 months, primary outcomes were time-to-inactive-disease and time-to-flare after DMARD discontinuation. Secondary outcomes were adapted ACRPedi30/50/70/90 scores, functional ability and adverse events. Results 94 children (67 % girls) aged median (IQR) 9.1 (4.6–12.9) years were enrolled: 32 in arms 1 and 2, 30 in arm 3. At baseline visual analogue scale (VAS) physician was mean 49 (SD 16) mm, VAS patient 53 (22) mm, erythrocyte sedimentation rate 12.8 (14.7), active joints median 8 (5–12), limited joints 2.5 (1–4.8) and Childhood Health Assessment Questionnaire score mean 1.0 (0.6). After 24 months, 71% (arm 1), 70% (arm 2) and 72% (arm 3) of patients had inactive disease and 45% (arm 1), 31% (arm 2) and 41% (arm 3) had drug-free inactive disease. Time-to-inactive-disease was median 9.0 (5.3–15.0) months in arm 1, 9.0 (6.0–12.8) months in arm 2 and 9.0 (6.0–12.0) months in arm 3 (p=0.30). Time-to-flare was not significantly different (overall 3.0 (3.0–6.8) months, p=0.7). Adapted ACR pedi-scores were comparably high between arms. Adverse events were similar. Conclusion Regardless of initial specific treatments, after 24 months of treatment-to-target aimed at drug-free inactive disease, 71% of recent-onset patients with JIA had inactive disease (median onset 9 months) and 39% were drug free. Tightly controlled treatment-to-target is feasible. Trial registration number 1574.
Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas
Authors: Hiroshi Urakawa, Yoshihiro Nishida, Ayako Mitsuma, Osamu Maeda, Mihoko Sugishita, Tomoya Shimokata, Takeshi Mizutani, Eisuke Arai, Kunihiro Ikuta, Shunsuke Hamada, Takehiro Ota, Naoki Ishiguro, Yuichi Ando
Journal: Annals of Oncology (2018)
GW29-e1121 Outcomes of Thoracic Endovascular Aortic Repair in Acute Complicated Type B Aortic Dissection in a single Chinese tertiary vascular referral center
Authors: Ziyu Zheng, Qiangqiang Liu, Jinli Liao, Ruibin Cai, Yan Xiong
Journal: Journal of the American College of Cardiology (2018)
Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604)
Authors: R.A. Huddart, F. Cafferty, J. White, J. Shamash, I.M. Hennig, M. Cullen, S. Stenning
Journal: Annals of Oncology (2018)
Re: Adrean et al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053)
Authors: Jesse J. Jung, Talia R. Kaden, K. Bailey Freund
Journal: Ophthalmology (2018)
David Oliver: Private GPs—a manufactured media scandal?
Authors: David Oliver
Journal: BMJ (2018)

During a weekend working on the acute medical unit I noticed a visitor reading a copy of the Mail on Sunday . A prominent headline caught my eye: “Can’t get in to see your doctor? Highly paid GPs accused of driving up waiting times by favouring lucrative private clients over NHS patients.” At home that evening I looked up the piece on the Mail ’s website.1

Three bold bullet points lay below the headline: “Many doctors work part time for the NHS, taking time out to see private patients”; “One in 30 GP consultations is privately paid for, netting doctors £550m a year”; and “A pressure group said it was ‘pretty obvious’ NHS patients would wait longer.”

What substance …